Organisation paid for research Program year 2020 Source: CMS Open Payments

Coastal Urology Associates

Neither a doctor nor a teaching hospital

Research payments

$94,917

47 payments

Through program year 2020, Coastal Urology Associates is reported as receiving $94,917 in research payments, across 47 payments.

By program year

2 rows
Year Kind Amount Payments
2020 Research $20 1
2019 Research $94,897 46

Breakdown

Who paid Research payments · program years 2019–2020
  1. Merck Sharp & Dohme Corporation $87,509 43 payments
  2. Spectrum Pharmaceuticals Inc. $7,408 4 payments
Studies the money was for Research payments · program years 2019–2020
  1. A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab MK-3475 in Combination with Bacillus Calmette-Guerin BCG in Participants with High Risk Non-muscle Invasive Bladder Cancer NMIBC that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 $54,131 2 payments
  2. A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676) $27,077 1 payment
  3. Spi-Qap-306 $7,408 4 payments
  4. A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab MK-3475 in Combination with Bacillus Calmette-Guerin BCG in Participants with High Risk Non-muscle Invasive Bladder Cancer NMIBC that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 $5,000 1 payment
  5. A Phase 3, Randomized, Comparator-Controlled Clinical Trial to Study the Efficacy of Pembrolizumab MK-3475 in Combination with Bacillus Calmette-Guerin BCG in Participants with High Risk Non-muscle Invasive Bladder Cancer NMIBC that is Persistent or Recurrent Following BCG Induction KEYNOTE-676 $1,280 38 payments
  6. A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that is either Persistent or Recurrent Following BCG Induction or that is Na ve to BCG Treatment KEYNOTE-676 $20 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record